Date of Award

2022

Document Type

Dissertation

Degree Name

Doctor of Philosophy (Ph.D.)

Department

Pharmaceutical and Chemical Sciences

First Advisor

Mamoun M. Alhamadsheh

First Committee Member

Miki S. Park

Second Committee Member

Qinliang Zhao

Third Committee Member

Wade Russu

Fourth Committee Member

Jesika Faridi

Abstract

A serious opioid crisis is affecting public health and economics, eroding people’s quality of life. 80% of patients who receive opioids suffer from adverse effects such as Opioid-induced constipation (OIC). However, there is no efficient medicine for these adverse effects. Notably, mainstream theory supports that analgesia effects are mainly controlled by CNS while OIC is predominately controlled by peripheral. In addition, the sites of action of opioid was based on the assumption that mu-opioid receptor antagonists (PAMORAs), did not cross the blood-brain barrier (BBB). Unfortunately, the BBB crossing of PAMORAs mislead the understanding of the role of the central nervous system (CNS) and gastrointestinal tract playing in the adverse effects such as opioid-induced constipation (OIC). Here, we developed a novel technology platform to prevent drugs from crossing the BBB. By applying this technology, naloxone- and oxycodone conjugates demonstrated superior potency, peripheral selectivity, pharmacokinetics, and effectiveness in rats compared to currently clinically used PAMORAs. By the help of these probes, it is revealed for the first time to that the mu-opioid receptors in the CNS played more important role in OIC than the peripheral receptors, which overturned the old theory. And the new theory points the way to better future PAMORAs drug design.

Pages

117

Available for download on Saturday, September 07, 2024

Share

COinS